Myeloid leukemia, acute

A quickly progressive malignant disease in which there are too many immature blood-forming cells in the blood and bone marrow, the cells being specifically those destined to give rise to the granulocytes or monocytes, both types of white blood cells that fight infections. In AML, these blasts do not mature and so become too numerous. AML can occur in adults or children. Acute myeloid leukemia is abbreviated AML (pronounced A M L). It is also known as acute myelogenous leukemia or acute nonlymphocytic leukemia (ANLL).

The early signs of AML may be similar to the flu or other common diseases with fever, weakness and fatigue, loss of weight and appetite, and aches and pains in the bones or joints. Other signs of AML may include tiny red spots in the skin, easy bruising and bleeding, frequent minor infections, and poor healing of minor cuts.

First, blood tests are done to count the number of each of the different kinds of blood cells and see whether they are within normal ranges. In AML, the red blood cell levels may be low, causing anemia; platelet levels may be low, causing bleeding and bruising; and the white blood cell levels may be low, leading to infections.

A bone marrow biopsy or a bone marrow aspiration may be done if the results of the blood tests are abnormal. During a bone marrow biopsy, a hollow needle is inserted into the hip bone to remove a small amount of the marrow and bone for examination under a microscope. In a bone marrow aspirate, a small sample of liquid bone marrow is withdrawn through a syringe.

A lumbar puncture, or spinal tap, may be done to see if the disease has spread into the cerebrospinal fluid, which surrounds the central nervous system (CNS) — the brain and spinal cord.

Other key diagnostic tests may include flow cytometry (in which cells are passed through a laser beam for analysis), immunohistochemistry (using antibodies to distinguish between types of cancer cells), cytogenetics (to determine chromosome changes in cells), and molecular genetic studies (DNA and RNA tests of the cancer cells).

The primary treatment of AML is chemotherapy. Radiation therapy is less common; it may be used in certain cases. Bone marrow transplantation is coming into increasing use. When appropriate it can increase the likelihood of cure.

There are two phases of treatment for AML. The first phase is called induction therapy. The purpose of induction therapy is to kill as many of the leukemia cells as possible and induce a remission, a state in which there is no visible evidence of disease and blood counts are normal. Patients may receive a combination of drugs during this phase including daunorubicin, idarubicin, or mitoxantrone plus cytarabine and etoposide. Once in remission with no signs of leukemia, patients enter a second phase of treatment.

The second phase of treatment is called post-remission therapy (or consolidation therapy). It is designed to kill any remaining leukemic cells. In post-remission therapy, patients may receive high doses of chemotherapy, designed to eliminate any remaining leukemic cells. Treatment may include a combination of cytarabine, daunorubicin, idarubicin, etoposide, or mitoxantrone.

There are a number of different subtypes of AML. AML is classified using a system called the French American British (FAB) system. In the this system, the subtypes of AML are grouped according to the particular cell line in which the disease developed. There are eight distinct types of AML, designated M0 through M7. Types M2 (myeloblastic leukemia with maturation) and M4 (myelomonocytic leukemia) each account for 25% of AML; M1 (myeloblastic leukemia, with few or no mature cells) accounts for 15%; M3 (promyelocytic leukemia) and M5 (monocytic leukemia) each account for 10% of cases; the other subtypes are rarely seen. AML is also classified according to the chromosomal abnormalities in the malignant cells.

The treatment of the subtype of AML called acute promyelocytic leukemia (APL) differs from that for other forms of AML. (APL is M3 in the FAB system.) Most APL patients are now treated first with all-trans-retinoic acid (ATRA) plus an anthracycline type chemotherapy such as daunorubicin, idarubicin, or mitoxantrone or others which induces a complete response in 70% of cases and extends survival. APL patients are then given a course of consolidation therapy, which is likely to include cytosine arabinoside (Ara-C) and idarubicin. ATRA is continued during consolidation and maintenance in some patients. Arsenic trioxide may be used during 2nd remission induction following a relapse. Bone marrow transplantation is considered during 2nd remission.

1
2
Next